SEQUENZLISTE Claims (11) Applications Claiming Priority (7) Publications (2) Family ID=27385799 Family Applications (1) Country Status (15) Cited By (1) Families Citing this family (78) Family Cites Families (18) 2000 2000-06-28 US US09/606,501 patent/US6579968B1/en not_active Expired - Lifetime 2000-06-29 AU AU63407/00A patent/AU783718B2/en not_active Ceased 2000-06-29 JP JP2001505933A patent/JP4576493B2/en not_active Expired - Fee Related 2000-06-29 PT PT00950283T patent/PT1196184E/en unknown 2000-06-29 CA CA2376978A patent/CA2376978C/en not_active Expired - Lifetime 2000-06-29 MX MXPA02000111A patent/MXPA02000111A/en active IP Right Grant 2000-06-29 WO PCT/US2000/018217 patent/WO2001000224A1/en not_active Ceased 2000-06-29 BR BRPI0012200-9B1A patent/BR0012200B1/en not_active IP Right Cessation 2000-06-29 DE DE60019598T patent/DE60019598T2/en not_active Expired - Lifetime 2000-06-29 HK HK02107538.2A patent/HK1047881B/en not_active IP Right Cessation 2000-06-29 NZ NZ516030A patent/NZ516030A/en not_active IP Right Cessation 2000-06-29 AT AT00950283T patent/ATE293453T1/en active 2000-06-29 KR KR1020017016944A patent/KR101021632B1/en not_active Expired - Lifetime 2000-06-29 EP EP00950283A patent/EP1196184B8/en not_active Expired - Lifetime 2000-06-29 ES ES00950283T patent/ES2235921T3/en not_active Expired - Lifetime 2002 2002-01-04 US US10/040,547 patent/US6794489B2/en not_active Expired - Lifetime 2004 2004-09-20 US US10/946,969 patent/US20050037951A1/en not_active Abandoned
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
If your medication spent two days in transit without proper cold-chain shipping, those are two days of potential degradation that count against your usable window
Miracle d**g which makes people look older and unhealthy Load More Replies
Results at 6-8 weeks (reduced shedding) and 3-4 months (new growth)
